Medpace Holdings, Inc.
MEDPHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. At a $12.77B market cap, Medpace Holdings, Inc. ranks as a large-cap company within healthcare. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
Market Cap
$12.77B
Beta
1.19
P/E (TTM)
28.16
P/E (Fwd)
24.09
EPS (TTM)
$15.88
EPS (Fwd)
$18.56
ROE
77.3%
ROA
17.5%
Cash
$652.7M
Total Debt
$146.1M
Free CF
$490.7M
52W Change
50.1%
Annual Financials
Cash vs Debt
Medpace Holdings, Inc. holds $652.7M in cash against $146.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $490.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 77.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 17.5% further supports the picture of efficient asset utilization. Revenue has grown from $1.46B (2022) to $2.53B (2025), reflecting a 73% increase over the period.
With cash comfortably exceeding debt, MEDP has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Medpace Holdings, Inc.'s trajectory.